Cargando…

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer

EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients harboring EGFR activating mutations. However, inhibition response is easily attenuated by drug resistance, which is mainly due to bypass activation or downstream activation. Herein, we established osimertinib-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Xueli, Wang, Rui, Gu, Tingxuan, Ma, Fayang, Laster, Kyle Vaughn, Li, Xiang, Liu, Kangdong, Lee, Mee-Hyun, Dong, Zigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535870/ https://www.ncbi.nlm.nih.gov/pubmed/36203195 http://dx.doi.org/10.1186/s12943-022-01662-1

Ejemplares similares

The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations
por: Ma, Fayang, et al.
Publicado: (2022)

3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo
por: Ma, Fayang, et al.
Publicado: (2022)

Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts
por: Ma, Fayang, et al.
Publicado: (2021)

Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
por: Yin, Fanxiang, et al.
Publicado: (2022)

Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth
por: Xie, Xiaomeng, et al.
Publicado: (2021)

Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo
por: Huang, Hai, et al.
Publicado: (2021)

Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma
por: Liu, Fangfang, et al.
Publicado: (2021)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo
por: Fu, Xiaorong, et al.
Publicado: (2021)

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
por: Zhao, Zhi-Mei, et al.
Publicado: (2021)

Acetylshikonin inhibits inflammatory responses and Papain-like protease activity in murine model of COVID-19
por: Lu, Ning, et al.
Publicado: (2022)

CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology
por: Tian, Xueli, et al.
Publicado: (2019)

Costunolide Induces Apoptosis via the Reactive Oxygen Species and Protein Kinase B Pathway in Oral Cancer Cells
por: Huang, Hai, et al.
Publicado: (2021)

Ethyl Ferulate Suppresses Esophageal Squamous Cell Carcinoma Tumor Growth Through Inhibiting the mTOR Signaling Pathway
por: Pang, Mengjun, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
por: Jia, Xuechao, et al.
Publicado: (2023)

2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo
por: Zu, Xueyin, et al.
Publicado: (2020)

Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases
por: Song, Mengqiu, et al.
Publicado: (2023)

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2
por: Wang, Penglei, et al.
Publicado: (2023)

Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model
por: Gu, Tingxuan, et al.
Publicado: (2021)

Arbidol inhibits human esophageal squamous cell carcinoma growth in vitro and in vivo through suppressing ataxia telangiectasia and Rad3-related protein kinase
por: Yang, Ning, et al.
Publicado: (2022)

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer
por: Zhu, Chao, et al.
Publicado: (2019)

Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A
por: Bao, Zhuo, et al.
Publicado: (2022)

Reconstitution of the Costunolide Biosynthetic Pathway in Yeast and Nicotiana benthamiana
por: Liu, Qing, et al.
Publicado: (2011)

Potential Anti-Cancer Activities and Mechanisms of Costunolide and Dehydrocostuslactone
por: Lin, Xuejing, et al.
Publicado: (2015)

Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis
por: Procaccia, Shiri, et al.
Publicado: (2017)

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells
por: Iizuka-Ohashi, Mahiro, et al.
Publicado: (2018)

Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo
por: Shi, Xiaodan, et al.
Publicado: (2021)

Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC
por: Yang, Yang, et al.
Publicado: (2022)

Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
por: Kim, Dae Yong, et al.
Publicado: (2019)

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface
por: Belluomini, L., et al.
Publicado: (2021)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
por: Martinez-Marti, A, et al.
Publicado: (2017)

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
por: Bon, Giulia, et al.
Publicado: (2016)

The specific PKC-α inhibitor chelerythrine blunts costunolide-induced eryptosis
por: Ghashghaeinia, Mehrdad, et al.
Publicado: (2020)

Amelioration of Benign Prostatic Hyperplasia by Costunolide and Dehydrocostus Lactone in Wistar Rats
por: Choi, Dohyun, et al.
Publicado: (2021)

Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
por: Huang, Zheng, et al.
Publicado: (2023)

A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance
por: Qu, Fanjie, et al.
Publicado: (2021)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Extending the spectrum of AKT1 mosaicism: not just the Proteus syndrome
por: Polubothu, S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r0qak85sb0od9a0aml4hl9hlht